MONMOUTH JUNCTION, N.J.,
March 25, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company commercializing its European Union approved
CytoSorb® blood filter to treat life-threatening illnesses in the
intensive care unit, will report fiscal 2013 financial results
after the market close on Monday, March
31, 2014.
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q4 2013 and fiscal year ending
December 31, 2013, and answer
pre-submitted questions as time permits.
Conference Call Details:
Date: Monday, March 31,
2014
Time: 4:15 PM Eastern
Participant Dial-In: (480) 629-9760
Live Presentation Webcast:
http://public.viavid.com/index.php?id=108451
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed link:
http://public.viavid.com/index.php?id=108451
An archived recording of the conference call will be available
under the Investor Relations section of the Company's website at
http://www.cytosorbents.com/invest.htm
Investors are encouraged to submit their questions in advance as
soon as possible to Ms. Amy Vogel at
avogel@cytosorbents.com
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. CytoSorbents has numerous
products under development based upon this unique blood
purification technology, protected by 32 issued US patents and
multiple applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: http://www.cytosorbents.com/
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release are not promises or guarantees and
are subject to risks and uncertainties that could cause our actual
results to differ materially from those anticipated. These
statements are based on management's current expectations and
assumptions and are naturally subject to uncertainty and changes in
circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ
materially from those expressed or implied by the statements
herein. Risk factors are detailed in the Company's Form 10-K filed
with the SEC on April 3, 2013, which
is available at http://www.sec.gov.
Please Click to Follow us on Facebook and
Twitter
SOURCE CytoSorbents Corporation